Independent fund research. Built on SEC filings.

How we research funds

ETF · Technology Sector · ProShares

ProShares Ultra Nasdaq Biotechnology (BIB)

Ticker BIB · · Holdings as of May 31, 2026

Expense ratio
0.95%$95/yr per $10k
5-yr return
−1.0%annualized
1-yr return
+59.3%as of Dec 2025
Net assets
$73.7Mall share classes
Holdings
267

Bottom line

Is BIB a good fund? The bottom line

BIB is an actively managed technology sector ETF from ProShares.

Annual fees run 0.95% — about $95 a year on every $10,000 invested, more expensive than 67% of technology sector funds we track.

It returned +59.3% over one year, −1.0% a year over five years, +1.4% a year over ten (as of Dec 31, 2025, per its prospectus).

With $73.7 million in net assets and 267 holdings, its largest position is N/a (7.4%) and the top 10 make up 43% of the portfolio.

The closest lower-cost alternative we found is IBBQ (0.19%, 51% top-holdings overlap).

What stands out

  • Broadly diversified (267 holdings)

What to watch

  • 5-year return in the bottom quarter of its category

Updated Nov 19, 2026

What BIB invests in

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index (the Index).

The Fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The Index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. The Index includes companies listed on the Nasdaq Global Select Market or the Nasdaq Global Market (which include both U.S. and non-U.S. companies) that are included in the biotechnology or pharmaceuticals subsectors, according to the Industry Classification Benchmark. The biotechnology and pharmaceutical subsectors include companies engaged in research into and development of biological substances for the purposes of drug discovery and diagnostic development and manufacturers of prescription or over-the-counter drugs. Companies are selected based on market capitalization and liquidity. Selected companies are then…

From the fund's prospectus (filed Sep 25, 2026).

BIB performance

Fund calendar-year total returns, 2016–2025 2016: −44.2%; 2017: +40.8%; 2018: −24.4%; 2019: +45.5%; 2020: +39.7%; 2021: −5.9%; 2022: −28.6%; 2023: −1.3%; 2024: −10.0%; 2025: +59.3% −44% 2016 +41% 2017 −24% 2018 +46% 2019 +40% 2020 −6% 2021 −29% 2022 −1% 2023 −10% 2024 +59% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
BIB+59.3%−1.0%+1.4%
Technology Sector median+24.0%+10.0%+16.7%

Source: Fund prospectus, as of Dec 31, 2025

Full BIB performance history →

What BIB costs

On a $10,000 investment, BIB's 0.95% expense ratio costs about $95 a year. The prospectus estimates $1,401 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.

See the full BIB fee table →

BIB top 10 holdings

#Holding% of fund
1N/a7.35%
2ProShares GENIUS Money Market ETF6.80%
3Gilead Sciences, Inc.4.66%
4Vertex Pharmaceuticals, Inc.4.65%
5Amgen, Inc.4.48%
6N/a3.94%
7N/a3.26%
8Regeneron Pharmaceuticals, Inc.3.21%
9N/a2.62%
10Alnylam Pharmaceuticals, Inc.2.01%

Source: SEC Form N-PORT, period ended May 31, 2026

The top 10 make up 43% of the fund. See all top 25 holdings and asset mix →

Alternatives to BIB

Closest equivalent at other fund companies
FamilyFundExpense ratioOverlap
InvescoIBBQ Invesco Nasdaq Biotechnology ETF0.19%51% Compare

More funds like BIB →

BIB FAQ

What is the expense ratio of BIB?
BIB's expense ratio is 0.95%, which works out to about $95 a year for every $10,000 invested. The prospectus estimates total costs of $1,401 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is BIB a good investment?
It depends on your goals, but the data points to: broadly diversified (267 holdings); 5-year return in the bottom quarter of its category. This is general information, not personalized advice.
What does BIB hold?
BIB's largest holdings are N/a (7.4%), ProShares GENIUS Money Market ETF (6.8%), Gilead Sciences, Inc. (4.7%), Vertex Pharmaceuticals, Inc. (4.7%), Amgen, Inc. (4.5%). It holds 267 positions in total as of May 31, 2026 (SEC Form N-PORT).
What is BIB's 5-year return?
BIB returned −1.0% a year over the five years ending Dec 31, 2025, and +1.4% a year over ten years. Past performance does not guarantee future results.
What is a cheaper alternative to BIB?
IBBQ (Invesco Nasdaq Biotechnology ETF) overlaps about 51% with BIB and charges 0.19%.
Who manages BIB?
BIB is offered by ProShares through Proshares Trust.